The electric vehicle market once experienced unlimited glory, $Nikola (NKLA.US)$ (NKLA.US) as a star company in hydrogen fuel electric trucks, reached a peak market cap of 30 billion USD, but just a few years later it fell into bankruptcy crisis, with stock prices plummeting more than 95%。
This inevitably makes investors think:Does the electric vehicle market still hold investment value? How should investors avoid similar risks? This article will provide an in-depth analysis from the key factors leading to Nikola's collapse, the current state of the electric vehicle market, and future investment opportunities in three main aspects.
The rise and fall of Nikola: from a Market Cap of 30 billion to near bankruptcy.
1. Market Bubble and Exaggerated Promotion
Nikola went public in June 2020, and the stock price once soared to 93.99 USD, with a Market Cap exceeding 30 billion USD, at one point comparable to Ford (F.US). The market's high expectations for Hydrogen Fuel Tech have made Nikola the rising star in the electric vehicle Industry.
However, the problem was that Nikola at that timedid not have any truly mass-produced vehicles, and many technology claims were questioned. For example,Hindenburg Research released a short-selling report in September 2020, accusing Nikola Exaggerating technological capabilities and even falsifying demonstrations of the truck's running.This led to damage to the company's reputation and a sharp decline in stock prices.
2. Management scandals and the collapse of investor confidence...

$Crown LNG (CGBS.US)$ Reuters· 5 mins ago
Crown LNG Signs Gas Sales Mou With India Gas Exchange

For those currently suffering losses, Hold is the best choice.
Stopping losses is the most incorrect choice, 📉 20-40% 📈 80-100%.
Because you are not losing much anymore, shorts need to cover to raise prices, the opportunity is just a moment away.
Make your own choices with your own stocks.
$MGO Global (MGOL.US)$

$Innate Pharma (IPHA.US)$
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Monday, 17th February at 1:02 am
• Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety profile in patients with advanced Sézary syndrome heavily pre-treated, post- mogamulizumab.
• Breakthrough Therapy Designation is intended to accelerate the development and regulatory review in the U.S. of dru...

$Virpax Pharmaceuticals (VRPX.US)$ The selling pressure is so strong~

$Bolt Projects (BSLK.US)$ trash stock

$CNS Pharmaceuticals (CNSP.US)$ its over